Bayer's Stroke Drug Breakthrough and Board Reshuffle Signal a Pivotal Phase

Bayer's Asundexian cuts stroke risk by 26% in late-stage trial, offering a blockbuster prospect. The breakthrough coincides with a board refresh and mixed 2026 cash flow outlook.

A significant clinical breakthrough and a boardroom refresh are converging at Bayer as the German conglomerate navigates a critical period. The company’s experimental stroke prevention drug, Asundexian, has delivered compelling late-stage trial results, offering a potential blockbuster just as shareholders prepare to vote on new supervisory board members.

Published in the New England Journal of Medicine, data from the OCEANIC-STROKE study showed Asundexian reduced the risk of ischemic strokes in high-risk patients by 26% compared to a placebo, without increasing the risk of major bleeding. The drug, which works by selectively inhibiting the FXIa protein, was particularly effective against severe outcomes, cutting paralyzing or fatal strokes by 31%. These findings mark a dramatic reversal for a compound whose development was halted nearly three years ago, and Bayer is now preparing regulatory submissions.

This scientific success arrives alongside corporate changes set for Bayer’s Annual General Meeting on April 24. Shareholders will vote on two new candidates for the supervisory board: Alfred Stern, CEO of OMV, and former Cargill and Sara Lee executive Marcel Smits. They are slated to replace long-standing members Paul Achleitner and Colleen Goggins, who are stepping down.

Financially, the company presents a mixed picture. Bayer’s net financial debt fell by 8.5% to approximately €29.8 billion by the end of 2025, aided by operational cash flows and positive currency effects. However, management anticipates a substantial negative free cash flow of around €5 billion for 2026. The dividend will remain unchanged at €0.11 per share.

Operational guidance for the year remains steady. The company is targeting currency-adjusted sales of up to €47 billion and an EBITDA before special items of around €10 billion. Management has stated that new U.S. pharmaceutical tariffs are already fully factored into its 2026 plans. The company also aims to realize €2 billion in savings through its Dynamic Shared Ownership model.

On the sustainability front, Bayer has achieved its strongest rating profile to date. MSCI upgraded the company to an AA rating, while Sustainalytics removed its "Red Flag" status in late 2025, citing improved litigation risk management related to glyphosate.

Bayer’s share price has gained nearly 10% since the start of the year, trading at around €40. This level sits just above its 100-day moving average of €39.93, indicating a thin buffer for the stock. All eyes are now on the first-quarter results due in May, which must demonstrate that the confirmed annual outlook is backed by solid day-to-day operations.